Berberine
A plant alkaloid that rivals metformin for blood sugar.
Moderate evidence
🫀Heart & Metabolic
Evidence tier
Moderate
Research weight
Citations
18 verified / 18
Classification
Heart & Metabolic
❝
What the evidence says. Graded moderate: large meta-analyses show berberine lowers fasting glucose, HbA1c and LDL about as much as early-stage metformin, but absorption is poor, most trials are small or of modest quality, and it is not a substitute for prescribed therapy. (Moderate evidence: Several controlled trials; effects real but modest or context-dependent.)
What is Berberine?
Berberine is a heart and metabolic supplement used for blood-sugar control. NutriDex grades the human evidence as Moderate. Berberine activates AMPK, a key metabolic regulator. Meta-analyses show it lowers fasting glucose and HbA1c comparably to early-stage metformin, while also reducing LDL cholesterol and triglycerides. It is one of the more impressive natural metabolic agents, though absorption is poor and GI side effects are common. Not a substitute for prescribed diabetes therapy without medical guidance.
Purported Benefits
✓Blood-sugar control
✓Lower cholesterol
✓Insulin sensitivity
✓Weight support
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Blood-sugar control (type 2 diabetes)Large RCT meta-analyses (37-46 trials) show HbA1c down ~0.6-0.7% and fasting glucose down ~0.8 mmol/L, comparable to early metformin, without raising hypoglycemia. | Strong | ↑ benefit · moderate | 5 |
| Lower cholesterol / lipidsMeta-analyses show meaningful drops in LDL-C, total cholesterol and triglycerides with a favorable safety profile across dyslipidemia trials. | Strong | ↑ benefit · moderate | 4 |
| Insulin sensitivity (HOMA-IR)Multiple RCT meta-analyses report reduced HOMA-IR and fasting insulin, including in NAFLD; mostly Chinese-trial-heavy with poor absorption caveats. | Moderate | ↑ benefit · moderate | 3 |
| Weight / obesity indicesMeta-analysis found modest reductions in body weight (-0.88 kg), BMI and waist circumference; statistically significant but small. | Moderate | ↑ benefit · small | 2 |
| Drug-interaction risk (harm)Human crossover and transplant PK studies show berberine inhibits CYP3A4/2D6/2C9 and P-gp, raising levels of midazolam and cyclosporine—clinically relevant interactions. | Moderate | ⚠ risk | 2 |
Dosing & Compounds
Typical Dose
500 mg, 2–3× daily with meals (1,000–1,500 mg/day total).
Active Compounds
Safety & Cautions
Common GI upset and cramping. A potent CYP3A4/2D6/2C9 and P-glycoprotein inhibitor, so it raises blood levels of many drugs (e.g. statins, cyclosporine, midazolam) and adds to the glucose-lowering of diabetes medicines — watch for hypoglycaemia. Avoid in pregnancy and breastfeeding (can displace bilirubin and cause neonatal jaundice/kernicterus). Educational only — always check with your doctor or pharmacist before combining Berberine with any medicine.
Berberine drug interactions
Known or theoretical interactions between Berberine and common medications — educational, not exhaustive. Always check with your doctor or pharmacist before combining Berberine with any medicine.
Caution
Insulin & oral antidiabetics
Additive blood-glucose lowering; may cause hypoglycemia with diabetes drugs.
Berberine activates AMPK and improves insulin sensitivity, adding to antidiabetic agents. MSKCC — Berberine
Key Studies ★ 18 studies
Meta-analysis
Asbaghi 2023 (umbrella meta-analysis)
✓ PubMed
Umbrella meta-analysis of RCTs (searched to April 2023) found berberine supplementation significantly reduced fasting blood glucose, HbA1c, insulin, HOMA-IR, and the inflammatory markers IL-6, TNF-alpha, and CRP in patients with metabolic disorders.
Meta-analysis
Nie 2024 (systematic review/meta-analysis)
✓ Full text
Meta-analysis of RCTs in non-alcoholic fatty liver disease found berberine significantly improved liver enzymes (ALT, AST, GGT), lipid profile, HOMA-IR, and BMI, supporting its use as an adjunct therapy for NAFLD.
Meta-analysis
Effects of administering berberine alone or in combination 2024 (meta-analysis)
✓ PubMed
Systematic review and meta-analysis of RCTs in type 2 diabetes reported berberine, alone or combined with standard therapy, significantly reduced HbA1c (MD -0.73%), fasting glucose (MD -0.86 mmol/L), 2-hour glucose, fasting insulin, HOMA-IR, and BMI versus control.
meta-analysis
Wei 2024 (PCOS meta-analysis)
✓ PubMed
Meta-analysis of 10 RCTs (713 women with polycystic ovary syndrome) found berberine added to standard Western medicine significantly increased ovulation rate (RR 1.41), clinical pregnancy rate (RR 1.96), and endometrial thickness (+1.62 mm), while lowering luteinizing hormone and total testosterone.
meta-analysis
Ma 2023 (cardiovascular disease meta-analysis)
✓ PubMed
Systematic review and meta-analysis of 44 RCTs (4,606 patients) found berberine, especially combined with statins, significantly reduced NIHSS stroke score, hs-CRP, IL-6, TNF-alpha, and carotid intima-media thickness with no serious adverse reactions.
meta-analysis
Effect of berberine on obesity indices 2025 (Int J Obes meta-analysis)
✓ Full text
Systematic review and meta-analysis of RCTs in adults found berberine modestly but significantly reduced body weight (MD -0.88 kg), BMI (MD -0.48 kg/m2), and waist circumference (MD -1.32 cm), with no significant change in waist-to-hip ratio.
Meta-analysis
Nie (NAFLD meta-analysis) 2024
✓ PubMed
Meta-analysis of 10 RCTs (811 NAFLD patients): berberine significantly reduced ALT (SMD -0.72), AST (SMD -0.79), GGT (SMD -0.62), triglycerides (SMD -0.59), total cholesterol (SMD -0.74), LDL-C (SMD -0.53), HOMA-IR (SMD -1.56) and BMI (SMD -0.58), with only mild GI adverse events.
Meta-analysis
Guo 2022 (systematic review/meta-analysis)
✓ Full text
Meta-analysis of 37 RCTs (3,048 patients with type 2 diabetes) found berberine reduced fasting plasma glucose by ~0.82 mmol/L, HbA1c by ~0.63%, and 2-hour postprandial glucose by ~1.16 mmol/L without increasing adverse events or hypoglycemia.
Meta-analysis
Zamani 2022 (dose-response meta-analysis)
✓ Full text
Systematic review and dose-response meta-analysis of RCTs in adults found berberine supplementation significantly lowered total cholesterol, LDL-C, triglycerides, fasting glucose, HbA1c, and CRP while modestly improving cardiovascular risk factors.
Meta-analysis
Guo (46-RCT meta-analysis) 2021
✓ PubMed
Meta-analysis of 46 RCTs in type 2 diabetes: berberine (alone or adjunctive) reduced HbA1c (MD -0.73%), fasting plasma glucose (MD -0.86 mmol/L), 2-h postprandial glucose (MD -1.26 mmol/L), HOMA-IR (MD -0.71), LDL (MD -0.86 mmol/L) and triglycerides (MD -0.50 mmol/L), and raised HDL (MD +0.17 mmol/L), with a favorable safety profile.
Meta-analysis
Xie (37-RCT meta-analysis) 2022
✓ PubMed
Meta-analysis of 37 RCTs (3,048 type 2 diabetes patients): berberine reduced FPG (WMD -0.82 mmol/L), HbA1c (WMD -0.63%) and 2-h postprandial glucose (WMD -1.16 mmol/L); glucose-lowering scaled with baseline FPG/HbA1c and did not increase total adverse events (RR 0.73) or hypoglycemia (RR 0.48).
Meta-analysis
Zamani (dose-response meta-analysis) 2022
✓ PubMed
Systematic review and dose-response meta-analysis of RCTs in adults: berberine lowered triglycerides (WMD -23.7 mg/dL), total cholesterol (-20.6 mg/dL), LDL (-9.6 mg/dL), FBG (-7.7 mg/dL), HbA1c (-0.45%), HOMA-IR (-1.04), systolic BP (-5.5 mmHg), weight and BMI, and raised HDL (+1.4 mg/dL); optimal lipid/weight dose ~1 g/day.
Meta-analysis
Lan 2015 meta-analysis
✓ PubMed
Comparable glucose-lowering to oral hypoglycemics.
Meta-analysis
Ju (dyslipidaemia meta-analysis) 2018
✓ PubMed
Meta-analysis of 16 RCTs (2,147 participants) in dyslipidaemia: berberine reduced total cholesterol (MD -0.47 mmol/L), LDL-C (MD -0.38 mmol/L) and triglycerides (MD -0.28 mmol/L), and raised HDL-C when used alone (MD +0.08 mmol/L), with no significant difference in adverse events (RR 0.64) and no severe events.
Meta-analysis
Dong 2012 meta-analysis
✓ Source
Significant reductions in total and LDL cholesterol.
rct
Guo 2012 (human CYP450 crossover RCT)
✓ PubMed
Randomized crossover study in healthy men found berberine 300 mg three times daily for 2 weeks inhibited CYP2D6, CYP2C9, and CYP3A4 activity (e.g., raising midazolam AUC ~40%), indicating potential for clinically relevant drug-drug interactions.
Study
Yin 2008
✓ PubMed
Improved glycemic control and lipids in type-2 diabetics.
clinical study
Wu 2005 (berberine-cyclosporine clinical/PK study)
✓ PubMed
Clinical and pharmacokinetic study in 104 renal transplant recipients found co-administration of berberine raised cyclosporine A blood concentrations (~29% higher steady-state, AUC +34.5%), demonstrating a clinically important interaction via CYP3A4/P-gp inhibition.